2025-04-24 - Analysis Report
## Natera Inc. (NTRA) Stock Analysis Report

**0. Executive Summary:**

Natera Inc. (NTRA) is a genetic testing company.  Its cumulative return significantly outperforms the S&P 500 (VOO), though recent performance has been volatile.  Financial performance shows increasing revenue but negative ROE, suggesting potential growth challenges.  Short-term price movement indicates a slight upward trend, although it's below its 60-day moving average.


**1. Performance Comparison:**

Natera Inc. (NTRA) shows a cumulative return of 125.58%, considerably higher than the S&P 500's (VOO) 73.52%. The difference is 52.1 percentage points, placing it at the 15th percentile of historical performance relative to the S&P 500 based on the provided range (max: 622.1, min: -48.4).

**Alpha and Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | -6.0%   | 62.4%   | -0.1   | 1.2   |       |
| 2016-2018  | 29.0%   | 80.1%   | 0.0    | 1.9   |       |
| 2017-2019  | 159.0%  | 80.1%   | 1.3    | 4.5   |       |
| 2018-2020  | 530.0%  | 80.1%   | 0.7    | 13.4  |       |
| 2019-2021  | 355.0%  | 62.9%   | 0.3    | 12.6  |       |
| 2020-2022  | -119.0% | 62.9%   | 0.3    | 5.4   |       |
| 2021-2023  | -482.0% | 69.9%   | 1.3    | 8.5   |       |
| 2022-2024  | -75.0%  | 70.6%   | 1.3    | 21.4  |       |
| 2023-2025  | 74.0%   | 72.8%   | 0.9    | 20.1  |       |

The high volatility of CAGR and significant negative values in recent years indicate substantial risk.  While Alpha is often positive, suggesting outperformance, the Beta values show high sensitivity to market movements.


**2. Recent Price Movement:**

* **Closing Price:** $148.56
* **5-Day Moving Average:** $146.73
* **20-Day Moving Average:** $144.38
* **60-Day Moving Average:** $154.16

The current price is below the 5-day, 20-day, and 60-day moving averages, suggesting a potential downward trend. The recent price increase of $2.72 compared to the previous close suggests a possible short-term rebound.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4174 (Medium Risk)
* **RSI:** 53.70 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.56 (Positive, suggesting potential upward momentum)
* **Relative Strength Change (20-day):** -0.7 (Short-term downward trend)
* **Expected Return (2+ years):** 108.1% (Significant outperformance of the S&P 500 is expected over the long term).

The increase in price from the previous close might be a short-term rebound. The high expected return is promising for long-term investors, but the volatility needs to be considered.

**4. Recent Earnings Analysis:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-11-12 | -$0.26   | $0.44B      |
| 2024-08-09 | -$0.30   | $0.41B      |
| 2024-05-10 | -$0.56   | $0.37B      |
| 2023-11-09 | -$0.95   | $0.27B      |
| 2024-11-12 | -$0.95   | $0.27B      |


Revenue is increasing, but EPS remains negative, indicating consistent losses.  The duplicate entry for 2024-11-12 needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2024-12-31 | $0.48B     | 62.94%        |
| 2024-09-30 | $0.44B     | 61.79%        |
| 2024-06-30 | $0.41B     | 58.83%        |
| 2024-03-31 | $0.37B     | 56.72%        |
| 2023-12-31 | $0.31B     | 51.38%        |

Revenue is growing steadily, and profit margins remain relatively high.


**Capital and Profitability:**

| Quarter    | Equity     | ROE        |
|------------|------------|------------|
| 2024-12-31 | $1.20B     | -4.50%     |
| 2024-09-30 | $0.88B     | -3.60%     |
| 2024-06-30 | $0.84B     | -4.48%     |
| 2024-03-31 | $0.79B     | -8.51%     |
| 2023-12-31 | $0.77B     | -10.20%    |

Despite increasing revenue and high profit margins, the Return on Equity (ROE) remains consistently negative, raising concerns about the company's profitability and efficiency in utilizing its equity.


**6. Overall Conclusion:**

NTRA exhibits significant long-term growth potential, indicated by its strong historical outperformance against the S&P 500 and a high projected future return. However, the stock's considerable volatility and consistently negative ROE present substantial risk.  The recent downward price trend and negative EPS warrant caution.  Further investigation into the reasons for negative ROE and the duplicate earnings data is crucial before making any investment decision.  A long-term investment strategy with a high risk tolerance might be suitable, but careful monitoring is necessary due to the inherent volatility.
